Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.

Li B, Meng Y, Zheng L, Zhang X, Tong Q, Tan W, Hu S, Li H, Chen Y, Song J, Zhang G, Zhao L, Zhang D, Hou S, Qian W, Guo Y.

Cancer Res. 2013 Nov 1;73(21):6471-83. doi: 10.1158/0008-5472.CAN-13-0657.

2.

Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.

Zheng L, Tan W, Zhang J, Yuan D, Yang J, Liu H.

Cancer Immunol Immunother. 2014 Jun;63(6):581-6. doi: 10.1007/s00262-014-1541-z.

PMID:
24668364
3.

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

Huang X, Wang S, Lee CK, Yang X, Liu B.

Cancer Lett. 2011 Aug 1;307(1):72-9. doi: 10.1016/j.canlet.2011.03.019.

PMID:
21497990
4.

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.

Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B.

Mol Cancer. 2013 Nov 11;12(1):134. doi: 10.1186/1476-4598-12-134.

5.

p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.

Bisaro B, Sciortino M, Colombo S, Camacho Leal MP, Costamagna A, Castellano I, Montemurro F, Rossi V, Valabrega G, Turco E, Defilippi P, Cabodi S.

Oncotarget. 2016 Jan 26;7(4):4442-53. doi: 10.18632/oncotarget.6710.

6.

Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.

Wang S, Chen C, Meng Y, Hu S, Zheng L, Song J, Zhang D, Li B, Guo Y.

Cancer Lett. 2012 Dec 28;325(2):214-9. doi: 10.1016/j.canlet.2012.07.007.

PMID:
22789781
7.

Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.

Fu W, Wang Y, Zhang Y, Xiong L, Takeda H, Ding L, Xu Q, He L, Tan W, Bethune AN, Zhou L.

MAbs. 2014 Jul-Aug;6(4):978-90. doi: 10.4161/mabs.28786.

8.

The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.

Han S, Meng Y, Tong Q, Li G, Zhang X, Chen Y, Hu S, Zheng L, Tan W, Li H, Chen Y, Zhang G, Li B, Guo Y.

MAbs. 2014 Mar-Apr;6(2):403-8. doi: 10.4161/mabs.27443.

9.

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.

Breast Cancer Res. 2013;15(5):R101.

10.

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD.

Sci Signal. 2013 Aug 13;6(288):ra68. doi: 10.1126/scisignal.2004008. Erratum in: Sci Signal. 2014 Sep 30;7(345):er5.

PMID:
23943608
11.

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.

Pedersen MW, Jacobsen HJ, Koefoed K, Dahlman A, Kjær I, Poulsen TT, Meijer PJ, Nielsen LS, Horak ID, Lantto J, Kragh M.

Mol Cancer Ther. 2015 Mar;14(3):669-80. doi: 10.1158/1535-7163.MCT-14-0697.

12.

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.

Mol Cancer Ther. 2012 Mar;11(3):582-93. doi: 10.1158/1535-7163.MCT-11-0820.

13.

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.

Ceran C, Cokol M, Cingoz S, Tasan I, Ozturk M, Yagci T.

BMC Cancer. 2012 Oct 4;12:450. doi: 10.1186/1471-2407-12-450.

14.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004.

PMID:
25128455
15.

Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.

Hamano S, Mori Y, Aoyama M, Kataoka H, Tanaka M, Ebi M, Kubota E, Mizoshita T, Tanida S, Johnston RN, Asai K, Joh T.

Cancer Lett. 2015 Jan 28;356(2 Pt B):846-54. doi: 10.1016/j.canlet.2014.10.046.

PMID:
25444894
16.

Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.

Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W.

Clin Cancer Res. 2008 Jul 15;14(14):4564-71. doi: 10.1158/1078-0432.CCR-08-0121.

17.
18.

In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.

Shen G, Huang H, Zhang A, Zhao T, Hu S, Cheng L, Liu J, Xiao W, Ling B, Wu Q, Song L, Wei W.

Cancer Immunol Immunother. 2011 Mar;60(3):339-48. doi: 10.1007/s00262-010-0937-7.

PMID:
21086124
19.

Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.

Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, Ako E, Tanaka H, Muguruma K, Sawada T, Hirakawa K.

Oncol Rep. 2012 Jul;28(1):49-54. doi: 10.3892/or.2012.1803.

PMID:
22562413
20.

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.

Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597.

Items per page

Supplemental Content

Support Center